Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-26Clinical Trial Results: Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency [Phase 2]
Phase 2 trial investigating docetaxel, carboplatin, and rucaparib camsylate in metastatic castration-resistant prostate cancer with homologo…
-
CLINICAL_TRIALS trial_result · 2026-08-26Clinical Trial Results: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating therapies for metastatic castration-resistant prostate cancer has terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-08-24Clinical Trial Results: A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating talazoparib in combination with temozolomide in prostate cancer has been terminated with posted results.
-
FDA approval · 2026-07-31FDA Approved: PLUVICTO — Supplemental Application (Novartis Pharmaceuticals Corporation)
Supplemental application for PLUVICTO (lutetium Lu-177 vipivotide tetraxetan) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2026-06-11Clinical Trial Results: Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway [Phase 2]
Phase 2 trial evaluating carboplatin in metastatic prostate cancer with homologous recombination pathway gene alterations completed with pos…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Cannabidiol for Pain Relief of Patients With End-stage mCRPC [Phase 2]
A Phase 2 clinical trial sponsored by Regionshospital Nordjylland is evaluating cannabidiol for pain relief in patients with metastatic cast…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer [Phase 3]
This Phase 3 trial is evaluating Xaluritamig in combination with Abiraterone vs investigator's choice in chemotherapy-naïve metastatic castr…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate [Phase 2]
A Phase 2 trial is evaluating talazoparib with or without enzalutamide in men with prostate cancer who have previously received abiraterone …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 [Phase 1, Phase 2]
Open-label Phase 1/2 trial of Pocenbrodib alone and in combination with Abiraterone acetate, Olaparib, or 177Lu-PSMA-617 is currently recrui…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors [Phase 2]
Phase 2 clinical trial update of ceralasertib (AZD6738) alone and in combination with olaparib or durvalumab in various solid tumors; the st…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]
This Phase 1 clinical trial from Roswell Park Cancer Institute is evaluating bipolar androgen therapy to restore sensitivity to androgen dep…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Bipolar Androgen Therapy + Carboplatin in mCRPC [Phase 2]
Phase 2 clinical trial evaluating bipolar androgen therapy in combination with carboplatin for castration-resistant prostate cancer, current…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC [Phase 1, Phase 2]
An early-phase Phase Ib/II open-label study evaluating AMO959 in combination with Lutetium-177 vipivotide tetraxetan (AAA617) and an androge…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: FOG-001 in Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
FOG-001 is being studied in a Phase 1/2 trial across multiple locally advanced or metastatic solid tumors and is currently recruiting; indic…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: First-Time-in-Human Study of GSK5471713 in Adults With mCRPC [Phase 1, Phase 2]
This clinical trial update notes the first-time-in-human study of GSK5471713 in adults with metastatic castration-resistant prostate cancer,…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression [Phase 1, Phase 2]
A Phase 1/2 trial evaluating enzalutamide in combination with ribociclib in metastatic castration-resistant prostate cancer retaining retino…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Clinical trial update indicating that JANX014 is being studied in Phase 1 for metastatic castration-resistant prostate cancer and is current…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) [Phase 3]
Phase 3 clinical trial update describing a study of Opevesostat (MK-5684) versus a next-generation hormonal agent in metastatic castration-r…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Study of DCC-2812 in Participants With Advanced Genitourinary Cancers [Phase 1]
This clinical trial update reports that a Phase 1 study of DCC-2812 in advanced genitourinary cancers (renal cell carcinoma, urothelial carc…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]
Phase I/II trial evaluating Pembrolizumab in combination with an androgen-receptor inhibitor, with or without 225Ac-J591, for progressive me…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: PRostate Olaparib Real World Evidence Study
A real-world evidence study evaluating Olaparib for metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 2]
This Phase 2 clinical trial assesses JSB462 (Luxdegalutamide) in combination with Lutetium-177 vipivotide tetraxetan for metastatic castrati…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial [Phase 2]
DIVINE is a Phase 2 trial evaluating stereotactic body radiation therapy with either immediate or delayed androgen receptor pathway inhibito…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). [Phase 3]
A Phase 3 clinical trial update for PF-06821497 (Mevrometostat) in men with metastatic castration-resistant prostate cancer who previously r…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating Ifinatamab Deruxtecan, as monotherapy or in combination, for metastatic castration-resistant pr…